Breast Cancer

Rebecca Chacko, MD, discussed exciting advancements in breast cancer care and the future role of emerging therapeutic strategies for early recurrence detection, as part of her panelist role at the Detroit Institute for Value-Based Medicine.

Rebecca Chacko, MD, discusses key breast cancer care challenges, including treatment access delays and the importance of open patient communication, as highlighted at the Detroit Institute for Value-Based Medicine session on unmet needs.

Estrogen-progestin hormone therapy used to manage menopausal symptoms and other women’s health conditions is associated with a higher risk of developing luminal-like breast cancer subtypes and other subtypes.

Sadie Dobrozsi, MD, of Evolent, discusses how predictive genomics is pushing cancer care into a new era of personalization

Women who developed a cardiovascular disease or type 2 diabetes were at a higher risk of developing breast cancer post menopause, a recent study found.

Dr Rugo discusses the promising outcomes of trastuzumab deruxtecan for HER2+ breast cancer, addressing interstitial lung disease risks and retreatment strategies.

Trastuzumab deruxtecan plus pertuzumab shows promising results as a potential new first-line treatment for HER2-positive breast cancer at ASCO 2025.

CK Wang, MD, explains that Black women face higher rates of late-stage breast and ovarian cancer diagnoses, demonstrating the need for better screening guidelines and more representative data.

Galen Shearn-Nance, BS, and Johnie Rose, MD, PhD, of Case Western Reserve University, acknowledge key limitations of their study and prioritize areas for further research.

No significant differences in treatment or outcomes were found between most Medicare Advantage (MA) and fee-for-service (FFS) beneficiaries with breast cancer, but Black patients with FFS Medicare were less likely to receive standard treatment.

As Medicare Advantage (MA) enrollment grows, Johnie Rose, MD, PhD, Case Western Reserve University School of Medicine, underscores the importance of ongoing research into outcomes for MA beneficiaries vs fee-for-service (FFS) Medicare beneficiaries.

This study examined postdiagnosis breast cancer treatment outcomes for Medicare Advantage vs fee-for-service (FFS) Medicare in Ohio and found no significant differences overall but disparities for Black patients with FFS Medicare.

Interval breast cancer rates have remained consistent over 30 years despite age-based screening, highlighting the need for risk-based screening strategies that account for factors like breast density, hormone replacement therapy, and family cancer history to improve early detection.

Jade E. Jones, MD, of Emory Winship Cancer Institute, shares how considering patients' travel needs, social services, and insurance concerns can help improve access to care.

Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health, provides new insights on the role of TROP2-directed antibody drug conjugates (ADCs) for patients with breast cancer.

For this retrospective study, the authors examined data on more than 3 million screening mammographies for more than 1 million female patients; of the screenings, 23.6% had abnormal results and only 6.7% were recommended for biopsy.

Racial and ethnic disparities were identified in immunotherapy receipt for Black patients with metastatic triple-negative breast cancer.

Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health, discusses findings from the TROPION-Breast01 study on datapotamab deruxtecan for patients with HR-positive/HER2-negative breast cancer.

A follow-up of the ShortHER trial suggests tumor-infiltrating lymphocytes (TILs) can help identify patients who may benefit from shorter trastuzumab and chemotherapy regimens.

Significant increases in breast cancer incidence were found among Hispanic, American Indian or Alaska Native, and Asian or Pacific Islander women.

Breast cancer screening rates shifted after the 2009 US Preventive Services Task Force (USPSTF) guidelines, with disparities emerging across race, income, and lifestyle factors.

Sarah Anderson, oncology strategy lead director, Novotech, discusses the significance of triple-negative breast cancer research in the Asia-Pacific region, and the importance of clinical trial diversity in this region.

Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted therapy.

Atezolizumab (Tecentriq) plus chemotherapy after surgery did not improve survival in high-risk triple-negative breast cancer, according to a global phase 3 trial.